Free Trial

DiaMedica Therapeutics (DMAC) Competitors

DiaMedica Therapeutics logo
$5.05 +0.17 (+3.48%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$5.29 +0.24 (+4.75%)
As of 07/25/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

DMAC vs. MRVI, IOVA, URGN, TLRY, TNGX, STOK, PRME, DNTH, PHAT, and UPB

Should you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Maravai LifeSciences (MRVI), Iovance Biotherapeutics (IOVA), Urogen Pharma (URGN), Tilray Brands (TLRY), Tango Therapeutics (TNGX), Stoke Therapeutics (STOK), Prime Medicine (PRME), Dianthus Therapeutics (DNTH), Phathom Pharmaceuticals (PHAT), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.

DiaMedica Therapeutics vs. Its Competitors

Maravai LifeSciences (NASDAQ:MRVI) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, media sentiment, risk, analyst recommendations, earnings and institutional ownership.

In the previous week, DiaMedica Therapeutics had 3 more articles in the media than Maravai LifeSciences. MarketBeat recorded 9 mentions for DiaMedica Therapeutics and 6 mentions for Maravai LifeSciences. Maravai LifeSciences' average media sentiment score of 0.90 beat DiaMedica Therapeutics' score of 0.67 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Maravai LifeSciences
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
DiaMedica Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

DiaMedica Therapeutics has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -67.14%. Maravai LifeSciences' return on equity of -12.91% beat DiaMedica Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Maravai LifeSciences-67.14% -12.91% -6.87%
DiaMedica Therapeutics N/A -61.35%-55.53%

DiaMedica Therapeutics has lower revenue, but higher earnings than Maravai LifeSciences. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Maravai LifeSciences$241.86M2.83-$144.85M-$1.14-2.36
DiaMedica TherapeuticsN/AN/A-$24.44M-$0.64-7.89

Maravai LifeSciences presently has a consensus price target of $6.64, suggesting a potential upside of 146.80%. DiaMedica Therapeutics has a consensus price target of $10.75, suggesting a potential upside of 112.87%. Given Maravai LifeSciences' higher probable upside, analysts plainly believe Maravai LifeSciences is more favorable than DiaMedica Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Maravai LifeSciences
1 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.25
DiaMedica Therapeutics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 2.1% of Maravai LifeSciences shares are held by insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Maravai LifeSciences has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.

Summary

Maravai LifeSciences and DiaMedica Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get DiaMedica Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DMAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DMAC vs. The Competition

MetricDiaMedica TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$209.27M$3.07B$5.70B$9.50B
Dividend YieldN/A2.37%4.60%4.01%
P/E Ratio-7.8921.1828.1020.05
Price / SalesN/A286.99429.3789.38
Price / CashN/A42.7636.2258.56
Price / Book5.328.378.665.87
Net Income-$24.44M-$55.19M$3.25B$258.55M
7 Day Performance20.81%5.88%4.22%3.73%
1 Month Performance32.55%17.33%10.51%11.75%
1 Year Performance38.74%4.42%34.40%18.03%

DiaMedica Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DMAC
DiaMedica Therapeutics
1.4964 of 5 stars
$5.05
+3.5%
$10.75
+112.9%
+36.9%$209.27MN/A-7.8920News Coverage
Insider Trade
MRVI
Maravai LifeSciences
3.6215 of 5 stars
$2.67
-2.2%
$6.64
+148.6%
-68.4%$679.94M$259.18M-2.34610Options Volume
IOVA
Iovance Biotherapeutics
4.6281 of 5 stars
$2.01
+7.5%
$12.22
+508.1%
-66.8%$671.20M$164.07M-1.62500Analyst Forecast
Options Volume
Gap Up
High Trading Volume
URGN
Urogen Pharma
4.5114 of 5 stars
$14.49
+1.8%
$32.86
+126.8%
+15.8%$668.13M$90.40M-4.56200
TLRY
Tilray Brands
1.8077 of 5 stars
$0.66
+13.1%
$1.92
+191.8%
-61.3%$661.07M$788.94M-0.632,650Upcoming Earnings
Options Volume
TNGX
Tango Therapeutics
1.6657 of 5 stars
$6.09
+2.7%
$12.20
+100.3%
-30.8%$660.12M$40.99M-4.9990Positive News
STOK
Stoke Therapeutics
4.2583 of 5 stars
$12.06
+1.7%
$24.75
+105.2%
-10.0%$658.48M$36.56M15.27100
PRME
Prime Medicine
3.8602 of 5 stars
$4.80
+10.3%
$10.08
+110.1%
-25.5%$645.57M$3.85M-2.34234Gap Down
High Trading Volume
DNTH
Dianthus Therapeutics
1.3354 of 5 stars
$20.03
-0.1%
$53.00
+164.6%
-23.5%$644.17M$6.24M-6.9580Positive News
PHAT
Phathom Pharmaceuticals
4.3202 of 5 stars
$9.06
-1.3%
$17.50
+93.2%
-14.6%$632.48M$55.25M-1.73110Positive News
UPB
Upstream Bio
1.9063 of 5 stars
$11.73
+2.2%
$56.50
+381.7%
N/A$631.00M$2.30M0.0038News Coverage

Related Companies and Tools


This page (NASDAQ:DMAC) was last updated on 7/26/2025 by MarketBeat.com Staff
From Our Partners